atenolol / Generic mfg. - LARVOL DELTA

Efficacy and Tolerability of Atenolol vs. Propranolol in Treating Infantile Hemangiomas (EADV 2026) - "The lower, though not statistically significant, rate of adverse events supports its favorable tolerability. Once-daily dosing may also represent a practical advantage for adherence in infants."

Clinical • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hypoglycemia • Sleep Disorder

Longitudinal Melanonychia Evaluated by Ex Vivo Dermoscopy with Incidental Follicular Epithelial Inclusions in Nail Matrix Biopsy (EADV 2026) - "Chronic medications included atenolol, amlodipine, hydrochlorothiazide, spironolactone, hydralazine, diosmin, omeprazole, and fluoxetine. The incidental finding of these epithelial structures during the investigation of melanonychias may or not be associated with melanocytic nevi. Further case accumulation and correlative clinico-histopathological studies are required to determine whether these structures reflect a reactive process, a developmental remnant with latent proliferative potential, or an epiphenomenon associated with specific nail matrix microenvironmental changes."

Biopsy • Preclinical • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Mood Disorders • Type 2 Diabetes Mellitus

Comparative the Efficacy of Interventions for Ulcerated Infantile Hemangiomas: a Systemic Review (EADV 2026) - "Recent phar- macological advancements, including propranolol, nadolol, and atenolol, offer promising results for managing ulcerated hemangiomas. Conclusions The management of ulcerated IHs necessitates a personalized, multidisciplinary strategy.Despite advancements in treatment, further research is needed to close existing knowledge gaps and support the creation of evidence-based clinical guidelines. Such progress would contribute to better therapeutic outcomes and enhance the overall well-being of infants and their families"

Clinical • Review • Dermatology • Pediatrics

Comparative real-world safety profiles of selective β1-adrenergic receptor blockers: A multi-database pharmacovigilance disproportionality study. (PubMed, Medicine (Baltimore)) - "To generate real-world, evidence-based recommendations for the safe use of selective β1-blockers, we compared the adverse event profiles of metoprolol, bisoprolol, and atenolol using 2 large pharmacovigilance systems. This real-world pharmacovigilance assessment identifies drug-specific patterns of disproportionate reporting that may inform hypothesis generation and individualized monitoring. Because spontaneous-reporting data cannot establish incidence or causality, the findings should complement, rather than replace, clinical judgment and confirmation in controlled or longitudinal data sources."

Adverse events • Clinical • Journal • Real-world evidence • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension • Nephrology • Psychiatry • Renal Disease

Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment. (PubMed, Front Pharmacol) - "Regarding the primary endpoint, intralesional bleomycin combined with oral propranolol yielded significantly higher excellent response rates than oral propranolol alone (RR = 1.55, 95% CI 1.28-1.89; high certainty). Topical timolol with intralesional lauromacrogol (RR = 7.98, 95% CI 1.52-41.79) and oral propranolol with corticosteroids (RR = 2.00, 95% CI 1.03-3.88) showed higher excellent response rates, supported by moderate-certainty evidence...Oral atenolol was associated with numerically lower recurrence rates compared to oral propranolol, but the difference did not reach statistical significance (RR = 0.64, 95% CI 0.32-1.28; moderate certainty)...Defining precise risk-benefit profiles requires rigorous head-to-head trials utilizing uniform outcome measures. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261388356; Identifier: CRD420261388356."

Journal • Retrospective data • Review • Oncology

Atenolol or Bisoprolol after Myocardial Infarction without Recorded Heart Failure. (PubMed, NEJM Evid) - "Among patients without recorded characteristics in an administrative database suggesting the presence of heart failure, initiation of atenolol after myocardial infarction was associated with a lower risk of major adverse cardiovascular events, but not all-cause mortality, at 2 years compared with bisoprolol. (Funded by PRAIRIE and others.)."

Journal • Observational data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Damanhour Teaching Hospital | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Anesthesia • Hypotension • Otorhinolaryngology

Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies. (PubMed, Cardiovasc Drugs Ther) - "Allopurinol is a widely used compound in medical practice for gout, and has been proven safe, economical and effective in other cardiovascular diseases. The recent approval of allopurinol as an orphan drug for the treatment of MFS by the European Medicines Agency (EMA) adds further value to its potential inclusion in standard medical therapy in the near future."

Journal • Review • Cardiovascular • Genetic Disorders • Gout • Inflammatory Arthritis • Rheumatology • FBN1

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparative analysis of infarct-reducing properties of ß1 -, ß2 -, and ß3 -adrenergicreceptor ligands in ischemia and reperfusion of the heart. (PubMed, Pharmacology) - "β 1 -AR blockade increases cardiac tolerance to I/R in vivo. β 2 -AR blockade and β 2 - AR stimulation do not affect cardiac resistance to I/R in vivo. β 3 -AR blockade does not affect cardiac resistance to I/R in vivo."

Journal • Anesthesia • Cardiovascular • Myocardial Infarction

Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database. (PubMed, Pharmacol Rep) - "This pharmacovigilance analysis identified multiple medications, spanning different therapeutic classes, that demonstrated a disproportionate association with reports of RPF. Notably, some drugs with well-established safety profiles also emerged as potential signals, warranting increased clinical awareness. While this analysis reveals pharmacovigilance signals suggestive of drug-induced RPF, the observational nature of FAERS data limits causal inference. These findings underscore the need for further clinical research and mechanistic studies to better understand the etiopathogenic role of these agents in RPF development."

Adverse events • Journal • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

An Analyte-Specific LC-IMS-HRMS Framework for Enhanced Identification Confidence in Target Screening of Contaminants in Complex Matrices. (PubMed, Anal Chem) - "Additionally, both differentiation based on CCS values (e.g., atenolol-practolol) and mandatory detection of predefined qualifiers (e.g., prometryn-terbutryn) decreased false positives. By incorporating the TIMS dimension and mandatory qualifiers as additional identification information, this work provides a robust framework for high-throughput environmental monitoring and human exposure assessment."

Journal

Immobilized horseradish peroxidase hybrid biocatalysts for degradation of pharmaceuticals and other emerging micropollutants. (PubMed, PLoS One) - "For example, full degradation was achieved for MBT (100%), meloxicam (99.5%) and caffeic acid (98.6%). In contrast, prometryn and MCPA showed only partial degradation, reaching 19.2% and 20%, respectively, and no degradation was observed for fluometuron and atenolol...For instance, roxithromycin degradation increased from 0.5% to 58.2% with ZnO-HRP, and for cimetidine, TiO₂-HRP improved degradation from 0.3% to 60.1% without HOBT and from 9.0% to 66.7% with HOBT...Finally, an integrated HRP enzyme and chemical oxidation remediation strategy was applied to degrade two pollutants, trimethoprim and DEET. For trimethoprim, TiO2-HRP combined with H2O2 and UV achieved approximately 30% degradation, while for DEET, both TiO2-HRP + H2O2 + UV and ZnO-HRP + H2O2 + UV resulted in around 40% degradation, thereby highlighting a novel application for these hybrid peroxidase-photocatalysts."

Journal

Recurrent Cardiac Arrest in a Pediatric Patient with Hypertrophic Cardiomyopathy and a Myocardial Bridge: Player or Spectator? (PubMed, Pediatr Cardiol) - "Atenolol was started after his second SCA at age 12. After a third SCA he was transitioned to Nadolol and Mexiletine, and underwent transvenous ICD implantation due to delayed shock secondary to under-sensing on epicardial system. He had two additional episodes of SCA, for which he was started on Amiodarone and transferred to our institution for transplant evaluation in the setting of biventricular systolic dysfunction...MB can cause significant compression leading to compromised coronary flow and myocardial ischemia distinct from the intrinsic underlying cardiomyopathy in HCM. Modifiable causes should be considered in cases of recurrent SCA, as treatment may alter prognostic implications."

Journal • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Myocardial Ischemia • Pediatrics • Transplantation

Transcellular permeation of small molecule drugs with permeation enhancers | Poster Board #D26 (ACS-Fall 2026) - "This work focuses on two PEs, sodium caprate (C10) and salcaprozate sodium (SNAC), and their influence on membrane structure and the free energy of permeation of neutral (mannitol, atenolol, ketoprofen, decanedecaol, and mucic acid) and charged (ketoprofen, propranolol, and salicylic acid) small molecule drugs. Analyses revealed that the membrane interior becomes more hydrophilic with PEs by providing more opportunities for drug-PE and drug-water hydrogen bonding—these interactions are correlated with a decrease in the central barrier of permeation. These results will pave the way as prototypes for future work regarding peptides, to account for the size and charged group dependency, and the extent to which it influences the free energy of permeation."

Sex-differential outcomes of beta-blocker therapy after myocardial infarction with preserved ejection fraction: a propensity-matched study of 554,110 patients (ESC 2026) - "Beta-blocker recipients (metoprolol, bisoprolol, carvedilol, or atenolol within 30 days) were compared with non-recipients (no beta-blocker within 90 days). We did not find the outright harm reported in REBOOT, but the therapeutic window in women is considerably narrower. These results argue against a one-size-fits-all approach and support incorporating sex into prescribing decisions for post-MI secondary prevention."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Hypertension • Hypotension • Myocardial Infarction

Anti-Resorptive Effects of Atenolol Are Associated With Altered Transcriptional Metabolic Profiles in Human Osteoclasts (ASBMR 2026) - No abstract available

Late-breaking abstract

Analysis of real water samples with AQbD microextraction using thymol-based NADES: implications of uncontrolled hypertension risk in Egypt. (PubMed, Anal Methods) - "This work developed a green analytical method for the simultaneous determination of three model antihypertensive agents from distinct classes, namely, furosemide, atenolol, and lisinopril, in water samples. A comprehensive greenness assessment using the GAPI, AGREE, BAGI, and EVG tools confirmed strong alignment with sustainable chemistry principles. By enabling multi-class extraction of antihypertensive drugs with a low-ecological-footprint NADES-based protocol, this method addresses a critical gap as no prior NADES-based method exists for these three therapeutic classes together, supporting environmental monitoring and clean water objectives."

Journal • Cardiovascular • Hypertension

Impact of chronic beta-blocker versus renin-angiotensin inhibitor use on outcomes after blunt pelvic trauma. (PubMed, Surgery) - "Prior use of β-blockers is correlated with significantly worse rates of hemorrhage, infection, and thromboembolic events after a traumatic pelvic fracture when compared with renin-angiotensin system inhibitors. This could be due to renin-angiotensin system inhibitors attenuating the post-traumatic inflammatory response system by blocking angiotensin II, which causes inflammation, oxidative stress, endothelial dysfunction, and vasoconstriction. These findings suggest that chronic cardiovascular therapy type may influence post-pelvic trauma outcomes, underscoring the need for further investigation."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pneumonia • Pulmonary Embolism • Respiratory Diseases • Septic Shock

Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report. (PubMed, Acta Derm Venereol) - No abstract available

Journal

Impact of atenolol on oyster hemocytes: a model for assessing pharmaceutical immunotoxicity. (PubMed, Environ Toxicol Chem) - "Furthermore, differences in response by agranulocytes and granulocytes were observed, supporting the need to evaluate hemocyte subpopulations along with the whole population. These findings suggest oyster hemocytes may be a useful tool in addressing the gap of knowledge in ecotoxicological impacts of emerging contaminants on marine organisms and can serve as a preliminary assessment of immunotoxicity of these contaminants prior to in-vivo experiments."

Journal

Black Elderberry Exposure in Apparent Idiopathic Mild Acute Pancreatitis: A Case Report. (PubMed, Cureus) - "Medication reconciliation revealed daily use of black elderberry extract along with chronic losartan, atenolol, niacin, aspirin, and latanoprost. Because occult biliary disease and medication co-exposure could not be definitively excluded, causality was conservatively classified as possible black elderberry-associated acute pancreatitis. This case reviews the importance of explicit supplement reconciliation in apparent idiopathic acute pancreatitis and the need for endoscopic ultrasound or magnetic resonance cholangiopancreatography after recovery in older adults when initial evaluation is unrevealing."

Journal • Cardiovascular • Dyslipidemia • Hepatology • Hypertension • Pain • Pancreatitis

Effect of atenolol versus ivabradine on heart rate variability in patients of schizophrenia with clozapine-induced tachycardia: a randomized controlled trial. (PubMed, Psychiatry Res) - P=N/A | "No significant between-group differences in HRV parameters were established between atenolol and ivabradine. Ivabradine could be a viable option in patients where atenolol is either contraindicated or not tolerated. Future larger multicentric studies are needed for greater generalisability."

Journal • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia

A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery. (PubMed, Medicine (Baltimore)) - "Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Effects of the beta1-selective blocker atenolol on bone loss in postmenopausal women: Results of a double-blind placebo-controlled randomized trial (ASBMR 2026) - No abstract available

Clinical • Osteoporosis